COMMUNIQUÉS West-GlobeNewswire

VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
05/06/2024
Trial will evaluate once-daily VYN201 gel in subjects with either active or stable nonsegmental vitiligo Top-line data from the 24-week double-blind portion of the trial expected in mid-2025 BRIDGEWATER, N.J., June 05, [...]
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024
05/06/2024
-- Poster highlights promising preclinical profile of ABI-6250 ahead of entry into the clinic, expected by end of 2024 -- SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq [...]
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2024
05/06/2024
Presentation to highlight statistically significant Phase 3 results of Tonmya™ (TNX-102 SL) for the management of fibromyalgia New Drug Application (NDA) submission to the FDA on track for the second half of 2024 [...]
Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer
05/06/2024
Oak Ridge, TN, June 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H [...]
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
05/06/2024
New long-term safety and efficacy data of investigational roflumilast cream 0.15% in mild to moderate atopic dermatitis will be presented in an oral session Preclinical data on ARQ-234, CD200R agonist, for the treatment [...]
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
05/06/2024
MALVERN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative [...]
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders
05/06/2024
Interim CEO employment contract consists solely of equity compensation Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE [...]
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
05/06/2024
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders [...]
Ocular Therapeutix® to Host Investor Day on June 13, 2024
05/06/2024
Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, [...]
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
05/06/2024
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced [...]
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
05/06/2024
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, [...]
Hydreight in Partnership with DSV Global and VS Digital Health Launches Telemedicine Solution That Helps Companies Launch A D2C Healthcare Brand In All 50 States
05/06/2024
Hydreight Technologies is launching this healthcare platform in partnership with VS Digital Health and DSV Global. The platform is called VSDHOne (Read as VSDH-One). VSDHOne Simplifies the entry challenges for companies [...]
Telix Announces Launch of Proposed Initial Public Offering in the United States
05/06/2024
MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (the “Company” or “Telix”) today announces the launch of its initial public offering in the United States (the “Offering”) of 17,000, [...]
Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer
05/06/2024
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024
05/06/2024
Providence, RI, June 05, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. ( NASDAQ: OCEA ), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today [...]
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
05/06/2024
STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management [...]
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/06/2024
RESEARCH TRIANGLE PARK, N.C., June 05, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 4,650 [...]
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
05/06/2024
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference in [...]
23andMe Launches New Genetic Report on Bipolar Disorder
05/06/2024
Provides 23andMe+ Premium members with insight into their likelihood of developing the serious mental health illness based on thousands of genetic variants SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- [...]

Pages